Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.

MLA

Chicharro, Pablo, et al. “Secukinumab Is Effective and Safe in the Long‐term Treatment of Plaque Psoriasis in a Daily Practice Setting: Multicenter Study in 384 Spanish Patients.” Dermatologic Therapy, vol. 35, no. 12, Dec. 2022, pp. 1–11. EBSCOhost, https://doi.org/10.1111/dth.15929.

APA

Chicharro, P., Llamas, V. M., Armesto, S., Herrera Acosta, E., Vidal, D., Vilarrasa, E., Rivera, D. R., De, la‐Cueva, P., Martorell, C. A., Ballescà, F., Belinchon, I., Carretero, G., Rodriguez, L., Romero, M. A., Pujol, M. J., Salgado, L., Sahuquillo, T. A., Coto, S. P., Baniandrés Rodríguez, O., & Feltes, R. (2022). Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy, 35(12), 1–11. https://doi.org/10.1111/dth.15929

Chicago

Chicharro, Pablo, Velasco, Mar Llamas, Susana Armesto, Enrique Herrera Acosta, David Vidal, Eva Vilarrasa, Diaz, Raquel Rivera, et al. 2022. “Secukinumab Is Effective and Safe in the Long‐term Treatment of Plaque Psoriasis in a Daily Practice Setting: Multicenter Study in 384 Spanish Patients.” Dermatologic Therapy 35 (12): 1–11. doi:10.1111/dth.15929.